Vanda Pharmaceuticals (VNDA) Gross Profit (2016 - 2025)
Vanda Pharmaceuticals' Gross Profit history spans 13 years, with the latest figure at $53.4 million for Q4 2025.
- On a quarterly basis, Gross Profit rose 5.51% to $53.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $203.1 million, a 8.32% increase, with the full-year FY2025 number at $203.1 million, up 8.32% from a year prior.
- Gross Profit hit $53.4 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $53.3 million in the prior quarter.
- Over the last five years, Gross Profit for VNDA hit a ceiling of $63.3 million in Q3 2021 and a floor of $35.8 million in Q3 2023.
- Historically, Gross Profit has averaged $52.1 million across 5 years, with a median of $53.3 million in 2025.
- Biggest five-year swings in Gross Profit: crashed 39.4% in 2023 and later grew 26.15% in 2024.
- Tracing VNDA's Gross Profit over 5 years: stood at $61.8 million in 2021, then fell by 5.73% to $58.2 million in 2022, then dropped by 28.21% to $41.8 million in 2023, then grew by 21.01% to $50.6 million in 2024, then increased by 5.51% to $53.4 million in 2025.
- Business Quant data shows Gross Profit for VNDA at $53.4 million in Q4 2025, $53.3 million in Q3 2025, and $49.9 million in Q2 2025.